Investor Intelligence
Your portfolio’s next big idea. Each week, our analysts and leading Wall-Street experts provide in-depth analysis that dives deep on a company, opportunity or trend in markets. Brought to you by Finimize, the #1 financial information platform for modern investors.
Investor Intelligence
Ozempic Made Novo Nordisk a Giant. Here's Why It's Stock Might Be Undervalued
•
Finimize
Ozempic’s still the hottest drug on the planet.
But Novo Nordisk’s stock? Not so much. It’s down nearly 50% from its peak, and investors aren’t sure whether to double down or walk away.
In today’s episode, Finimize Analyst Russell Burns, whose latest research unpack's what’s really going on with the stock, joins the pod.
Is this just a healthy correction? Or the kind of long-term opportunity you only get when everyone else is panicking?
